{"url_path":"/sec/gnpx/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1595248/0001437749-26-016755-index.html","accession_number":"0001437749-26-016755","cik":"0001595248","ticker":"GNPX","issuer_name":"Genprex, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1595248/0001437749-26-016755-index.html","primary_entity_key":"0001595248","primary_entity_name":"Genprex, Inc."},"word_count":749,"has_tables":true,"body_markdown":"gnpx20260331_10q.htm\n\n0001595248\nGenprex, Inc.\nfalse\n--12-31\nQ1\n2026\n\n0.001\n0.001\n10,000,000\n10,000,000\n0\n0\n0\n0\n0.001\n0.001\n200,000,000\n200,000,000\n9,044,856\n9,044,856\n3,291,488\n3,291,488\n3\n5\n243,622\n11.21\n377,780\n9.00\n0\n0\n0\n0\n0\n0\n0\n0\n5\n0\n10\n0\n0\n0\n1\n0\n0\n0\n15,000\nfalse\nfalse\nfalse\nfalse\nIncludes $19,553 and $420,226 of stock-based compensation expense for the three months ended September 30, 2025 and 2024, respectively, and $0 and $1,272 of depreciation and amortization expense for the three months ended September 30, 2025 and 2024, respectively. Includes $663,243 and $3,034,966 of stock-based compensation expense for the nine months ended September 30, 2025 and 2024, respectively, and $0 and $6,230 of depreciation and amortization expense for the nine months ended September 30, 2025 and 2024, respectively, inclusive of the amount stated in the preceding sentence\nIncludes $230,861 and $184,773 of stock-based compensation expense for the three months ended March 31, 2026 and 2025.\n\n00015952482026-01-012026-03-31\nxbrli:shares\n00015952482026-05-11\nthunderdome:item\niso4217:USD\n00015952482026-03-31\n00015952482025-12-31\niso4217:USDxbrli:shares\n00015952482025-01-012025-03-31\n0001595248us-gaap:CommonStockMember2025-12-31\n0001595248us-gaap:AdditionalPaidInCapitalMember2025-12-31\n0001595248us-gaap:RetainedEarningsMember2025-12-31\n0001595248us-gaap:CommonStockMember2026-01-012026-03-31\n0001595248us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-31\n0001595248us-gaap:RetainedEarningsMember2026-01-012026-03-31\n0001595248us-gaap:CommonStockMember2026-03-31\n0001595248us-gaap:AdditionalPaidInCapitalMember2026-03-31\n0001595248us-gaap:RetainedEarningsMember2026-03-31\n0001595248us-gaap:CommonStockMember2024-12-31\n0001595248us-gaap:AdditionalPaidInCapitalMember2024-12-31\n0001595248us-gaap:RetainedEarningsMember2024-12-31\n00015952482024-12-31\n0001595248us-gaap:CommonStockMember2025-01-012025-03-31\n0001595248us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-31\n0001595248us-gaap:RetainedEarningsMember2025-01-012025-03-31\n0001595248us-gaap:CommonStockMember2025-03-31\n0001595248us-gaap:AdditionalPaidInCapitalMember2025-03-31\n0001595248us-gaap:RetainedEarningsMember2025-03-31\n00015952482025-03-31\n0001595248gnpx:ExcludingElocPurchaseAgreementMember2026-01-012026-03-31\n0001595248gnpx:ExcludingElocPurchaseAgreementMember2025-01-012025-03-31\nxbrli:pure\n0001595248gnpx:ReverseStockSplitMember2025-10-212025-10-21\n0001595248us-gaap:EmployeeStockOptionMember2026-01-012026-03-31\n0001595248us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-31\nutr:Y\n0001595248srt:MinimumMember2026-03-31\n0001595248srt:MaximumMember2026-03-31\n0001595248gnpx:October2025RegisteredDirectOffering1Member2025-10-242025-10-24\n0001595248gnpx:October2025RegisteredDirectOffering1Member2025-10-24\n0001595248gnpx:October2025PrivateWarrants1Member2025-10-24\n0001595248gnpx:PlacementAgentWarrantsMember2025-10-24\n0001595248gnpx:PlacementAgentWarrantsMembersrt:MaximumMember2025-10-242025-10-24\n0001595248srt:MaximumMembergnpx:October2025RegisteredDirectOffering1Member2025-10-242025-10-24\n0001595248gnpx:October2025RegisteredDirectOffering2Member2025-10-292025-10-29\n0001595248gnpx:October2025RegisteredDirectOffering2Member2025-10-29\n0001595248gnpx:October2025PrivateWarrants2Member2025-10-29\n0001595248gnpx:PlacementAgentWarrantsMember2025-10-29\n0001595248gnpx:October2025PrivateWarrants2Member2025-10-29\n0001595248gnpx:October2025PrivateWarrants2Member2025-10-292025-10-29\n0001595248srt:MaximumMembergnpx:October2025RegisteredDirectOffering2Member2025-10-292025-10-29\n0001595248gnpx:The2023AtmFacilityMember2023-12-132023-12-13\n0001595248gnpx:The2023AtmFacilityMember2025-01-012025-03-31\n0001595248gnpx:The2023AtmFacilityMember2026-01-012026-03-31\n0001595248us-gaap:SubsequentEventMembergnpx:The2023AtmFacilityMember2026-04-012026-05-13\n0001595248gnpx:The2025ElocFacilityMember2025-06-112025-06-11\n0001595248gnpx:The2025ElocFacilityMember2026-03-31\n0001595248gnpx:ElocDerivativeMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001595248gnpx:ElocDerivativeMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001595248gnpx:ElocDerivativeMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001595248gnpx:ElocDerivativeMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001595248us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001595248us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001595248us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001595248us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001595248gnpx:ElocDerivativeMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001595248gnpx:ElocDerivativeMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001595248gnpx:ElocDerivativeMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001595248gnpx:ElocDerivativeMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001595248us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001595248us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001595248us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001595248us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001595248gnpx:ElocDerivativeMemberus-gaap:MeasurementInputSharePriceMember2026-03-31\n0001595248gnpx:ElocDerivativeMemberus-gaap:MeasurementInputSharePriceMember2025-12-31\n0001595248gnpx:ElocDerivativeMemberus-gaap:MeasurementInputPriceVolatilityMember2026-03-31\n0001595248gnpx:ElocDerivativeMemberus-gaap:MeasurementInputPriceVolatilityMember2025-12-31\n0001595248gnpx:ElocDerivativeMemberus-gaap:MeasurementInputExpectedTermMember2026-03-31\n0001595248gnpx:ElocDerivativeMemberus-gaap:MeasurementInputExpectedTermMember2025-12-31\n0001595248gnpx:ElocDerivativeMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2026-03-31\n0001595248gnpx:ElocDerivativeMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2025-12-31\n0001595248gnpx:The2025ElocFacilityMember2026-01-012026-03-31\n0001595248gnpx:The2025ElocFacilityMember2025-01-012025-03-31\n0001595248gnpx:ScientificAdvisoryBoardChairmanMember2026-01-012026-03-31\n0001595248us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-31\n0001595248gnpx:ScientificAdvisoryBoardChairmanMember2025-01-012025-03-31\n0001595248us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-31\n0001595248gnpx:March2024PrefundedWarrantsMember2026-01-012026-03-31\n0001595248gnpx:March2024PrefundedWarrantsMember2026-03-31\n0001595248gnpx:March2024PrefundedWarrantsMember2025-01-012025-03-31\n0001595248gnpx:OutstandingWarrantsMembersrt:MinimumMember2026-03-31\n0001595248gnpx:OutstandingWarrantsMembersrt:MaximumMember2026-03-31\n0001595248gnpx:The2018EquityIncentivePlanMember2018-04-03\n0001595248gnpx:The2018EquityIncentivePlanMember2018-04-032018-04-03\n0001595248gnpx:Amended2018EquityIncentivePlanMember2025-08-152025-08-15\n0001595248gnpx:Amended2018EquityIncentivePlanMember2025-01-012025-01-01\n0001595248gnpx:The2018EquityIncentivePlanMember2026-01-012026-01-01\n0001595248gnpx:Amended2018EquityIncentivePlanMember2026-03-31\n0001595248gnpx:The2018EmployeeStockPurchasePlanMember2018-04-03\n0001595248gnpx:The2018EmployeeStockPurchasePlanMember2026-03-31\nutr:M\n0001595248srt:MinimumMember2026-01-012026-03-31\n0001595248srt:MaximumMember2026-01-012026-03-31\n0001595248us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2026-01-012026-03-31\n0001595248us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2025-01-012025-03-31\n0001595248us-gaap:RestrictedStockUnitsRSUMember2025-12-31\n0001595248us-gaap:RestrictedStockUnitsRSUMember2024-12-31\n0001595248us-gaap:RestrictedStockUnitsRSUMember2026-03-31\n0001595248us-gaap:RestrictedStockUnitsRSUMember2025-03-31\n0001595248us-gaap:ResearchAndDevelopmentExpense2026-01-012026-03-31\n0001595248us-gaap:GeneralAndAdministrativeExpense2026-01-012026-03-31\n0001595248gnpx:TimebasedStockOptionAwardsRsusAndWarrantsMember2026-03-31\n0001595248gnpx:TimebasedStockOptionAwardsRsusAndWarrantsMembersrt:WeightedAverageMember2026-01-012026-03-31\n0001595248us-gaap:ResearchAndDevelopmentExpense2025-01-012025-03-31\n0001595248us-gaap:GeneralAndAdministrativeExpense2025-01-012025-03-31\n0001595248gnpx:TimebasedStockOptionAwardsRsusAndWarrantsMember2025-03-31\n0001595248gnpx:TimebasedStockOptionAwardsRsusAndWarrantsMembersrt:WeightedAverageMember2025-01-012025-03-31\n0001595248us-gaap:PerformanceSharesMember2026-03-31\n0001595248gnpx:PerformancebasedWarrantMember2026-03-31\n0001595248gnpx:MdAndersonMembergnpx:ResearchAgreementMember2018-07-012018-07-31\n0001595248gnpx:MdAndersonMembergnpx:ResearchAgreementMember2022-09-302022-09-30\n0001595248gnpx:MdAndersonMembergnpx:ResearchAgreementMember2024-01-012024-06-06\n0001595248gnpx:MdAndersonMembergnpx:ResearchAgreementMember2024-06-072024-06-30\n0001595248gnpx:MdAndersonMembergnpx:ResearchAgreementMember2024-01-012024-12-31\n0001595248gnpx:MdAndersonMembergnpx:ResearchAgreementMember2026-01-012026-03-31\n0001595248gnpx:NationalInstituteOfHealthMember2009-12-31\n0001595248gnpx:NationalInstituteOfHealthMember2009-01-012009-12-31\n0001595248us-gaap:LicenseAgreementTermsMember2021-03-03\n0001595248gnpx:NationalInstituteOfHealthMember2026-01-012026-03-31\n0001595248gnpx:NationalInstituteOfHealthMember2025-01-012025-03-31\n0001595248gnpx:NationalInstituteOfHealthMember2017-01-012017-03-31\n0001595248gnpx:NationalInstituteOfHealthMember2026-03-31\n0001595248gnpx:NationalInstituteOfHealthMember2025-12-31\n0001595248gnpx:NyuMembergnpx:LicenseAgreementMember2025-04-25\n0001595248gnpx:NyuMembersrt:MinimumMembergnpx:LicenseAgreementMember2025-04-25\n0001595248gnpx:NyuMembersrt:MaximumMembergnpx:LicenseAgreementMember2025-04-25\n0001595248gnpx:NyuMembergnpx:LicenseAgreementMember2026-01-012026-03-31\n0001595248gnpx:UniversityOfMichiganMembergnpx:LicenseAgreementMember2024-11-11\n0001595248gnpx:UniversityOfMichiganMembersrt:MinimumMembergnpx:LicenseAgreementMember2024-11-11\n0001595248gnpx:UniversityOfMichiganMembersrt:MaximumMembergnpx:LicenseAgreementMember2024-11-11\n0001595248gnpx:UniversityOfMichiganMembergnpx:LicenseAgreementMember2026-01-012026-03-31\n0001595248gnpx:UniversityOfMichiganMembergnpx:LicenseAgreementMember2025-01-012025-03-31\n0001595248gnpx:UniversityOfPittsburghMembergnpx:LicenseAgreementMember2025-02-17\n0001595248gnpx:UniversityOfPittsburghMembersrt:MinimumMembergnpx:RepresentsUsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1And2DiabetesMembergnpx:LicenseAgreementMember2025-02-17\n0001595248gnpx:UniversityOfPittsburghMembersrt:MaximumMembergnpx:RepresentsUsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1And2DiabetesMembergnpx:LicenseAgreementMember2025-02-17\n0001595248gnpx:UniversityOfPittsburghMembergnpx:RepresentsUsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1And2DiabetesMembergnpx:LicenseAgreementMember2025-02-17\n0001595248gnpx:UniversityOfPittsburghMembergnpx:LicenseAgreementMember2026-01-012026-03-31\n0001595248gnpx:UniversityOfPittsburghMembergnpx:LicenseAgreementMember2025-01-012025-03-31\n0001595248gnpx:UniversityOfPittsburghMembergnpx:RepresentsUsageOfAGlucagonPromoterAndGeneTherapyTechnologiesToPotentiallyTreatType1And2DiabetesMembergnpx:LicenseAgreementMember2025-05-02\n0001595248gnpx:UthealthHoustonMembergnpx:LicenseAgreementMember2025-05-02\n0001595248gnpx:UthealthHoustonMembersrt:MinimumMembergnpx:LicenseAgreementMember2025-05-02\n0001595248gnpx:UthealthHoustonMembersrt:MaximumMembergnpx:LicenseAgreementMember2025-05-02\n0001595248gnpx:UthealthHoustonMembergnpx:LicenseAgreementMember2025-05-022025-05-02\n0001595248gnpx:UthealthHoustonMembergnpx:LicenseAgreementMember2026-01-012026-03-31\n0001595248us-gaap:OperatingSegmentsMember2026-01-012026-03-31\n0001595248us-gaap:OperatingSegmentsMember2025-01-012025-03-31\n0001595248us-gaap:SubsequentEventMembergnpx:ScientificAdvisoryBoardChairmanMember2026-04-012026-04-01\n\n \n\n \n\n**UNITED STATES**\n\n \n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n \n\n**Washington, D.C. 20549**\n\n \n\n**FORM 10-Q**\n\n \n\n**(Mark One)**\n\n☒\n\n**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For the quarterly period ended March 31, 2026**\n\n**or**\n\n☐\n\n**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For the transition period from __________________ to ______________**\n\n \n\n**Commission File Number: 001-38244**\n\n \n\n**GENPREX, INC.**\n\n**(Exact name of registrant as specified in its charter)**\n\n \n\n**Delaware**\n\n**90-0772347**\n\n(State or other jurisdiction of\n\n(I.R.S. Employer\n\nincorporation or organization)\n\nIdentification No.)\n\n \n\n \n\n**3300 Bee Cave Road, #650-227, Austin, TX**\n\n**78746**\n\n(Address of principal executive offices)\n\n(Zip Code)\n\n \n\n**(512) 537-7997**\n\n(Registrant’s telephone number, including area code)\n\n \n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n**Title of each class**\n\n** **\n\n**Trading**\n\n**Symbol(s)**\n\n** **\n\n**Name of each exchange on which registered**\n\nCommon Stock, par value $0.001 per share\n\n \n\nGNPX\n\n \n\nThe Nasdaq Capital Market\n\n \n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒   No ☐\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒   No ☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. \n\n \n\nLarge accelerated filer\n\n☐\n\n \n\nAccelerated filer\n\n☐\n\nNon-accelerated filer\n☒\n \n\nSmaller reporting company\n\n☒\n\n \n\n \n\n \n\nEmerging growth company\n☐\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐  No ☒    \n\n \n\nAs of May 11, 2026, the registrant had 10,586,402 shares of common stock, par value $0.001 per share, outstanding.\n\n \n\n \n\n \n\n[Table of Contents](#toc)\n\n \n\n \n\n \n\n**GENPREX, INC.**\n\n**FORM 10-Q TABLE OF CONTENTS**\n\n** **\n\n \n\n \n\n \n\n \n\n**Page No.**\n\n \n\n \n\n \n\n \n\n** **\n\n**PART I**\n\n \n\n[**FINANCIAL INFORMATION**](#financialinfo)\n\n \n\n[3](#financialinfo)"}